Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anjun Cao

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Diabetes Care|December 1, 2016
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 DiabetesHelena W Rodbard, Anne L Peters, April Slee, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2002
Disrupted synaptic development in the hypoxic newborn brainSheila M Curristin, Anjun Cao, William B Stewart, et al.
The Lancet. Oncology|April 13, 2021
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trialMatthew J Matasar, Marcelo Capra, Muhit Özcan, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Diabetes Care|December 1, 2016
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 DiabetesHelena W Rodbard, Anne L Peters, April Slee, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2002
Disrupted synaptic development in the hypoxic newborn brainSheila M Curristin, Anjun Cao, William B Stewart, et al.
The Lancet. Oncology|April 13, 2021
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trialMatthew J Matasar, Marcelo Capra, Muhit Özcan, et al.
Pageof 1